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ABSTRACT: Production of β-lactamases (BLs) is the most widespread resistance
mechanism adopted by bacteria to ﬁght β-lactam antibiotics. The substrate spectrum of
BLs has become increasingly broad, posing a serious health problem. Thus, there is an
urgent need for novel BL inhibitors. Boronic acid transition-state analogues are able to
reverse the resistance conferred by class A and C BLs. We describe a boronic acid analogue
possessing interesting and potent broad-spectrum activity vs class A and C serine-based BLs.
Starting from benzo(b)thiophene-2-boronic acid (BZBTH2B), a nanomolar non-β-lactam
inhibitor of AmpC that can potentiate the activity of a third-generation cephalosporin
against AmpC-producing resistant bacteria, we designed a novel broad-spectrum nanomolar
inhibitor of class A and C BLs. Structure-based drug design (SBDD), synthesis, enzymology
data, and X-ray crystallography results are discussed. We clariﬁed the inhibitor binding
geometry responsible for broad-spectrum activity vs serine-active BLs using double mutant
thermodynamic cycle studies.
■ INTRODUCTION
Production of β-lactamases (BLs) (EC 3.5.2.6) is one of the
major mechanisms by which bacteria develop resistance to β-
lactam antibiotics. BLs are classiﬁed into serine-based BLs
(classes A, C, and D) and metallo-β-lactamases (MBLs), which
are class B BLs. These enzymes hydrolyze the amide bond in
the β-lactam ring, which constitutes the key feature of this type
of antibacterial agent. The substrate spectrum of BLs now
includes carbapenems and the latest generation of cephalospor-
ins.1
The use of a BL mechanism-based inhibitor in combination
with a β-lactam antibiotic is a well-established strategy to ﬁght
resistance.2 However, the three commercially available β-lactam
inhibitors (clavulanate, sulbactam, and tazobactam) are eﬀective
primarily against class A BLs (Figure 1B), while class C and D
enzymes are only poorly inhibited by any of the three
commercial inhibitors. Moreover, no clinically useful inhibitor
of MBLs has been identiﬁed to this point.3
These BL inhibitors share a β-lactam ring, making them
susceptible to resistance stemming from up-regulation of BL
production, selection for new BLs, and other mechanisms that
evolved over millions of years of chemical exposure between
bacteria and β-lactam-producing microorganisms (Figure
1B).4,5
Among class A plasmid-encoded BLs, TEM and CTX are the
most commonly observed extended-spectrum BLs (ESBLs);
they are found mainly in Escherichia coli and Klebsiella
pneumoniae and confer a high level of resistance to available
broad-spectrum cephalosporins. The TEM strains responsible
for nosocomial epidemics are usually multiresistant to anti-
biotics, and most of them produce ESBLs.1,6,7 CTX-M is a
group of class A BLs that are particularly resistant to extended
spectrum β-lactam antibiotics such as cefotaxime, which itself
was developed to counter bacterial resistance to ﬁrst-generation
penicillins and cephalosporins (Figure 1C).8 Since its discovery
in the late 1990s, CTX-M has become the most frequently
observed ESBL in many regions of the world.
These families of BLs present a signiﬁcant clinical threat,
with CTX-M-14 and CTX-M-15 being the most prominent
ESBLs worldwide and TEM BLs exhibiting the most variants.9
Regarding class C, resistance due to plasmid-mediated AmpC
enzymes is produced by BL overexpression, conferring
resistance to broad-spectrum cephalosporins (i.e., Enterobacter
aerogenes and Enterobacter cloacae infections) and causing outer-
membrane porin modiﬁcations (carbapenem resistance) and
plasmid transmission (E. coli, K. pneumoniae and Proteus
mirabilis infections).10
To treat antimicrobial multiresistant pathogens, a second-
generation BL inhibitor era has already begun, which mainly
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focuses on novel non-β-lactam inhibitors showing broad-
spectrum proﬁle.2,3,11−18 Derivatives such as avibactam and its
analogues have now reached in combination with ceftazidime
clinical phase II, representing a promising weapon against
bacterial resistance (Figure 1D).19−21 Conversely, an ideal MBL
inhibitor remains to be found despite the large number of
potential molecules already described.22
Among novel non-β-lactam inhibitors, we introduced
boronic acid transition-state analogues that bind to AmpC BL
with nanomolar aﬃnities: this novel chemistry was able to
reverse the resistance conferred by these enzymes, in particular
for those belonging to class C.16,18−20
Starting from benzo(b)thiophene-2-boronic acid
(BZBTH2B, compound 1, Figure 1A), a nanomolar non-β-
lactam inhibitor of AmpC able to potentate the activity of a
third-generation cephalosporin against class C-producing
resistant bacteria without inducing overexpression of AmpC,
we designed a broad-spectrum nanomolar inhibitor. Serine-
dependent BLs have similar folding and contain a S-X-X-K
motif, with serine acting as the catalytic residue. Starting from
the available crystal structure of compound 1 binding to the
AmpC active site and its visual analysis in comparison with class
A TEM-1 and CTX-M-9 BLs, we identiﬁed one potential
binding spot in the enzymes and a corresponding (or
reciprocal) chemical point of derivatization in the skeleton of
compound 1 that was exploited to produce stronger binding
aﬃnity and, most important, broad-spectrum activity.23−25 In
particular, our comparative analysis suggested the possibility of
introducing a polar, carboxylated lateral chain (i.e., 2-
carboxyvinyl) in compound 1 to gain new favorable electro-
static and H-bond interactions with the C3(4′)carboxylate
consensus binding pocket, common to all serine-active BLs.
The newly designed inhibitor, compound 5 (Figure 1E) was
then synthesized and tested, resulting in a potent and broad-
spectrum inhibitor. Its binding orientation in CTX-M-9 and its
critical binding interactions with TEM-1 were subsequently
clariﬁed and conﬁrmed by means of X-ray crystallography and
free energy double-perturbation thermodynamic analysis.
Thermodynamic cycles can be used to conﬁrm and/or
quantify the interaction between a functional group of a ligand
and an active site residue.26−29 In these experiments, wild-type
and “mutant” versions of both the enzyme and ligand are used,
with each “mutant” lacking the interacting groups of interest.
The energetic costs of removing the ligand functional group
both in the presence and absence of the residue with which
interactions occurs are calculated. The diﬀerence between these
energies provides the energy involved in the key interaction.
Quantitative knowledge of the energy exploited in the new
interaction between compound 5 and BLs exposed the
interactions that were critical for binding to TEM-1 and
indicated fundamental directions for further optimization.
■ RESULTS AND DISCUSSION
3-D Comparative Analysis of Serine-Based BLs and
Inhibitor Design. Starting from compound 1, we were
interested in obtaining a validated lead compound with
conserved or improved aﬃnity vs class C and, most important,
with extended activity vs class A. To localize the more
appropriate point of derivatization and to rationally select the
chemical groups suitable for derivatization, we referred to three
X-ray structures. The complex of AmpC BL with compound 1
(PDB code 1C3B)23 and the two complexes of SMS2, a
glycylboronic acid inhibitor ((1R)-1-(2-thienylacetylamino)-1-
(3-carboxyphenyl)methylboronic acid) (Figure 1F) binding
TEM-1 (PDB code 1NXY)24 and CTX-M-9 (PDB code
1YM1),30 were analyzed (2a,b). X-ray structures for com-
parative analysis were selected based on the broad activity
spectrum of SMS2. In the derivatization of glycylboronic acids,
the introduction of a carboxyphenyl group not only improved
the aﬃnity toward AmpC but, most important, also extended
the spectrum of inhibition vs TEM-1 and CTX-M-9 via
hydrogen-bond with Arg244 in TEM-1 and Arg276 in CTX-M-
9. Both residues are located in the β-lactam carboxylate binding
pocket.31 Our approach was guided by previous results: within
boronic acid, a carboxy group designed to mimic the C3(4)′
carboxylate of β-lactam substrates is a key recognition feature in
class A and C β-lactamases.15,24,25
The lead compound 1 in the AmpC binding site (PDB code
1C3B) forms quadrupole−quadrupole interactions with Tyr221
and quadrupole−dipole interactions with Asn152 (Figure 2a).
Distances and angles are consistent with quadrupolar
Figure 1. β-Lactamases inhibitors and β-lactam antibiotics. (A)
Starting lead compound 1, BZBTH2B, benzo(b)thiophene-2-boronic
acid. (B) The BL inhibitor clavulanic acid. (C) Cefotaxime, III
generation cephalosporin. (D) The last generation BL inhibitor
avibactam. (E) Broad spectrum inhibitor compound 5, 3-(2-
carboxyvinyl)benzo(b)thiophene-2-boronic acid. (F) Inhibitor SMS2
((1R)-1-(2-thienylacetylamino)-1-(3-carboxyphenyl)methylboronic
acid.
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interactions observed in other protein structures.32,33 An
observed interaction is the hydrogen bond between the boronic
acid O2 atom and Tyr150. Two well-ordered water molecules
appear in the active site, making extensive interactions that
involve the inhibitor and Tyr150. The ﬁrst water molecule
interacts through a hydrogen bond with the boronic acid O2
atom and with the active site residue Thr316. The second water
molecule forms a hydrogen bond with the ﬁrst water molecule.
This second water molecule also interacts with catalytic
residues Asn346 and Arg349. Additionally, the boronic acid
O1 atom hydrogen binds with the backbone nitrogens of Ser64
and Ala318 and also with the carbonyl oxygen of Ala318.23
Regarding the binary complex of TEM-1 binding SMS2
(PDB code 1NXY),24 we can observe that the inhibitor adopts
a deacylation transition-state analogue conformation in which
the boronic acid O1 atom is still in the “oxyanion” while the
conﬁguration around the boron has inverted; therefore, the
boronic acid O2 atom hydrogen binds with the catalytic base
Glu166, displacing the ordered, catalytic water molecule
(Figure 2b).34 The phenyl ring of SMS2 stacks with the
aromatic ring of Tyr105, making quadrupole interactions.32,33
The carboxylate group hydrogen binds with Arg244, Ser235,
and an ordered and highly conserved water molecule. These
interactions between Arg244, Ser235, and water are also seen
with the C3(4)′carboxylate of β-lactams, consistent with our
carboxylated inhibitor designed to mimic this ubiquitous
substrate group (Figure 2b).35
In the binary complex CTX-M-9−SMS2 (PDB code 1YM1),
key interactions between the boronic acid group and CTX are
analogous to those already described for TEM-1. The aromatic
ring of the inhibitor makes van der Waals contacts with the
aromatic ring of Tyr105 (distances from 3.3 and 4.6 Å).
Moreover, it is 3.0 Å away from the Ser130 Oγ atom, with the
hydroxyl group perpendicular to the face of the ring, in a typical
dipole−quadrupole interaction geometry.32 The carboxylic acid
groups of SMS2 interact with Oγ1 of Thr235 and three well-
ordered water molecules in the ubiquitous C3(4′)carboxylate
binding pocket, as previously observed in TEM-1 complexes.
Arg-276, which is implicated in the catalytic process of CTX-M
enzymes, in one monomer interacts with the m-carboxy group
of SMS2 via an ordered water molecule.24
When the three structures were superimposed for compar-
ison, in addition to the main diﬀerences in the residues between
class A and class C, position 3 of lead compound 1 always
pointed toward key residues involved in the C3(4)′carboxylate
interactions, namely Asn346 and Asn289 in AmpC (distance,
8.74 Å Nδ2 Asn346), Arg244 (8.14 Å NH1 Arg244), and
Ser235 (8.92 Å Oγ Ser235) in TEM-1 and Arg276 in CTX-M-9
(8.28 Å NH2 Arg276) (Figure 2c).
Figure 2. (a−c). 3-D comparative analysis of class A and C β-
lactamases guided inhibitor design. (a) Binary complex of BZB2THB
in AmpC BL. Key residues and interactions are highlighted. Carbon
atoms are in green, nitrogen atoms are colored blue, oxygen atoms red,
and sulfur atoms yellow. Red spheres represent water molecules.
Picture was prepared using CCP4mg.53 (b) Glycylboronic acid
inhibitor SMS2 complexes with CTM-M-9 (carbon atoms in blue)
and TEM-1 (carbon atoms in orange) are superimposed. The
interactions with C3(4′)carboxylate binding pocket of β-lactams are
highlighted. Nitrogen atoms are colored blue, oxygen atoms red, and
Figure 2. continued
sulfur atoms yellow. Red spheres represent water molecules. Picture
was prepared using CCP4mg.53 (c) Molecular surface of the
superimposed active site region of CTX-M-9, TEM-1, and AmpC.
Glycylboronic acid inhibitor SMS2 complexes with CTM-M-9 (carbon
atoms in blue) and TEM-1 (carbon atoms in orange) were
superimposed with BZB2THB in complex with AmpC (carbon
atoms in green). The C3(4′)carboxylate binding pocket of β-lactams
and the C3 position in BZB2THB selected for chemical derivatization
are highlighted. The surface contributed by nitrogen atoms is colored
blue, oxygen atoms are colored red, and carbon atoms are colored
gray. Picture was prepared using CCP4mg.53
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The visual analysis identiﬁed position 3 in lead compound 1
as the most convenient derivatization point to introduce
appropriate chemical groups able to reach the carboxylate
binding site delimited in AmpC by Thr316 and Asn346, by
Arg244 in TEM-1 and by Arg276 in CTX-M-9 (Figure 2c).36
Having selected and conﬁrmed position 3 for chemical
derivatization, we decided to introduce a 2-carboxyvinyl chain
able to mimic the distance, chemistry, and interactions of SMS2
C3(4)′phenylcarboxylate (Compound 5, Table 1). Compound
4, the keto analogue of compound 5, was additionally
synthesized as a tool for free energy double-perturbation
thermodynamic cycle, thus conﬁrming our hypothesis of the
importance of the carboxylate moiety in modulating aﬃnity and
potency vs BLs.
Synthesis. 2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-
benzo[b]thiophene-3-carbaldehyde (3) was designed and
synthesized as a scaﬀold for synthetic elaboration. We ﬁrst
reported the formylation reaction of compound 2 as a key step
in the derivatization at the 3 position of compound 1. In
Scheme 1, we report the synthetic route for the synthesis of
compound 4 and 5. The boronic acid group of 1 was protected
using 2,3-dimethyl-2,3-butanediol, and the resulting compound
2 was treated with dichloromethyl methyl ether in the presence
of Tin(IV) chloride to produce compound 3 with 75% yield. A
Wittig reaction from 3 and 1-(triphenylphosphoranylidene)-2-
propanone in a 1:1 molar ratio was performed to produce
compound 4 as pinacol-protected boronic acid. A Wittig
reaction between tert-butoxycarbonylmethylene-triphenylphos-
phorane and compound 3, followed by hydrolysis, was
performed, yielding compound 5 as pinacol-protected boronic
acid.
BLs Inhibition Studies. To investigate the eﬀectiveness of
the new analogues, we employed CTX-M-9, TEM-1, and
AmpC BLs and a UV absorbance-based biochemical assay to
obtain binding aﬃnities. As previously reported for other
boronic acid inhibitors of BLs, tested compounds were
competitive inhibitors and no incubation eﬀect was detected.
The inhibitory activity of analogues 4 and 5 carrying a lateral
chain at position 3 of compound 1 was evaluated, with the
expectation that compound 5 would form favorable electro-
static interactions with the carboxylate binding pocket of BLs,
as previously described. As expected, the 3-carboxy derivatives
3-(2-carboxyvinyl)benzo(b)thiophene-2-boronic acid (com-
pound 5) showed broad-spectrum activity vs classes A and C;
compound 5 inhibits with low nanomolar potency class A,
while its aﬃnity vs AmpC was not diminished compared to the
starting lead, compound 1 (Ki vs TEM-1 and CTX-M-9 40 nM,
Ki vs AmpC 90 nM, Table 1). On the other hand, compound 4,
bearing a keto group instead of a carboxy group, maintains
nanomolar aﬃnity vs AmpC (8 times less active) but loses
potency vs class A, highlighting how critical the carboxylic
group in class A is for molecular recognition (125 times less
active vs class A with respect to class C). Moreover, compound
5 was also tested vs the AmpC mutant N289A, in which the
wild-type asparagine is replaced by an alanine; its aﬃnity was
not reduced (Ki 50 nM vs N289A), thus supporting the
hypothesis that in AmpC the carboxylate interacts with Asn346,
as the β-lactam do and not with the adjacent Asn289.
X-ray Crystallographic Structure Determination. To
investigate the structural basis for the relative aﬃnities and to
understand the details of recognition along the reaction
coordinates, we determined the crystal structure of CTX-M-9
enzymes in complex with compound 5 to 1.50 Å resolution.
Excluding proline and glycine, 91.5% of residues were in the
favored region, 8.0% of residues were in the allowed region of
the Ramachandran plot, and only 0.4%, were in the generously
Table 1. Ki Values of BZB2THB Derivatives vs Serine β-
Lactamases
Scheme 1a
a(a) 2,3-Dimethyl-2,3-butanediol, dry ethyl ether, RT; (b) tin chloride, dichloromethyl methyl ether, dichloromethane, −20 to 0 °C ; (c) 1-
(triphenylphosphoranylidene)-2-propanone, dry dichloromethane, RT; (d) tert-butoxycarbonylmethylene-triphenyl posphorane, dry dichloro-
methane, RT; (e) dichloromethane triﬂuoroacetic acid, 50%, RT.
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allowed region.37 Several double conformations were revealed,
some of which were involved in active site geometry (chain A,
59, 98, 186, 201, 222, 262, 271, and 281; chain B, 75, 89, 113,
158, 186, 237, 249, 274, and 281). In the binding site, the
position of inhibitor 5 was unambiguously identiﬁed in the
initial Fo − Fc electron density diﬀerence map contoured at 1σ
(Figure 3a). Electron density connects the Oγ of the catalytic
Ser70 to the boron atom of boronic acid. The geometry of the
boronic acid group is tetrahedral (Figure 3a,b). In the CTX-M-
9−compound 5 complex, the 021 boronic acid hydroxyl
interacts via a hydrogen bond with the “oxyanion” hole N and
the O backbone atom of residue 237 (distance 2.88 and 2.74 Å,
respectively, in chain A, Figure 3b, Table 2) and N of Ser70
(distance 2.69 Å in chain A, Figure 3b, Table 2). The 022
boronic acid hydroxyl interacts with Oδ1Asn170 (2.63 Å) and
with Oε1 Glu166 (2.66 Å), replacing the catalytic water
molecule, which is not present in this complex. In this structure,
the O22 atom represents the position of the catalytic water
molecule in the deacylation transition state, consistent with
similar interactions observed in a TEM-1 boronic acid
structure.38 Overall, the boronic acid complex of compound 5
adopts a conformation consistent with a deacylation transition-
state analogue.39 The benzothiophene ring interacts with
Tyr105 (C15−CβTyr105, 3.4 Å). The lateral chain of
compound 5 makes contact with Ser130 (CβSer130−C18 3.4
Å). The carboxylic acid groups of compound 5 interact with
surrounding residues and a well-ordered water molecule in a
network diﬀerent from one chain to the other. In chain A, O23
interacts with the Oγ1 of Thr235 (O23−Oγ1Thr235 2.75 Å),
with Gly236 (NG236− O23 3.10 Å) and via a well-ordered
water molecule with Tyr105 (O23−Wat410 2.70 Å, Wat410−
OHTyr105 3.6 Å). O23 also interacts with three well-ordered
water molecules in an extended H-bond network that involves
Arg-276, which is implicated in the catalytic process of CTX-M
enzymes.40 This residue adopts a diﬀerent conformation in
chain B; the interaction between Arg276 and the carboxylate
group is closer, and only one ordered water molecule mediates
the H-bond (NεArg276−Wat229 2.98 Å, Wat229−O23 3.2 Å).
Moreover, in chain B as well as in chain A, several well-ordered
water molecules participate in an extended H-bond network
stabilizing the complex. The described interaction pattern is
consistent with the predicted inhibitor carboxylate group role:
the introduced chemistry mimics the ubiquitous C(3)4′
substrate carboxylate, as previously observed in the TEM and
CTX complexes.24,25
Double Mutant Thermodynamic Cycle Analysis (DPA).
To study the energetic eﬀect of the 3-(2-carboxy-vinyl) group
on compound 5 activity vs TEM-1, a double-perturbation
analysis was performed. Although it was clear from the X-ray
complex CTX-M-9−5 that the 3-(2-carboxy-vinyl) group
interacts via hydrogen bond with Arg276, the energies of
these interactions were unknown. In addition, lacking a 5−
TEM-1 X-ray complex, we wanted to conﬁrm this key
interaction also for TEM-1. For instance, moving from 1 to
Figure 3. (a) Electron density of compound 5 in complex with CTM-M-9. The 2Fo − Fc electron density map is represented by the green cage and
is contoured at 1.0σ. The inhibitor is covalently attached to Ser70. Carbon atoms of CTM-M-9 and compound 5 are colored green, Nitrogen atoms
are colored blue, oxygen atoms red, and sulfur atoms yellow. Picture was prepared using Pymol.54 (b) Key interactions observed in the complex of 5
with CTM-M-9, site B. The inhibitor is covalently attached to Ser70. Carbon atoms of CTX are colored gray, carbon atoms for 5 are colored green.
Nitrogen atoms are colored blue, oxygen atoms red, and sulfur atoms yellow. Red spheres represent water molecules. Residues Ser130 and Ser237
are in double conformation. Picture was prepared using CCP4mg.53
Table 2. Key Interactions in the Complex Structure
distance (Å)
interactions monomer A monomer B
S70N−O21 2.76 2.69
S237N−O21 2.94 2.88
S237O−O21 2.78 2.74
S130Oγ−O24 3.63 3.34
E166Oε1−O22 2.59 2.66
E166Oε2−O22 3.33 3.32
N170Oδ1−O22 2.65 2.63
N170Nδ2−O22 3.19 3.26
G236N−O23 3.10
T235Oγ1−O23 2.75 3.34
T235Oγ1−O24 3.42 2.46
K234Nζ−O24 2.94 3.45
Wat 61−O23 2.86
Wat482−O23 3.19
Wat 488−O23 2.82
Wat229−O23 3.20
R276Nε−Wat229 2.98
Wat410−O23 2.70
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its (2-carboxy-vinyl) derivative 5, binding energy vs TEM-1
improves by 2.8 kcal/mol, but it was unclear how much of this
energy is speciﬁcally derived from the hydrogen bond with
Arg276. This binding energy could alternatively result from
ionic interactions between the carboxylate and positively
charged protein residues, or through hydrogen bonds with
ordered water molecules. Quantitative knowledge of the energy
of these interactions is critical to the design of future derivatives
of 5, as those interactions responsible for the high aﬃnity of the
lead compound should be preserved in any future iteration.
Moreover, DPA could ﬁll the gap of information derived from a
missing compound 5−TEM-1 X-ray complex.
To quantify the energetic contributions of the hydrogen
bond with Arg276 in CTX-M-9, to conﬁrm the role of the
carboxyl group in the H-bond interaction in TEM-1 and to
deﬁnitively identify which residue in TEM-1 was involved in
the aforementioned interaction, we prepared DPA. In the
experiments, we used wild-type and “mutant” versions of both
the enzyme and ligand, with each “mutant” lacking the
interacting groups of interest (Scheme 2a). The energetic
cost, ΔΔG, of removing the ligand functional group both in the
presence and the absence of the residue with which it interacts
was calculated, and the diﬀerence between these energies,
ΔΔΔG, is the energy of the interaction (Scheme 2b).
Compound 5 loses its aﬃnity vs TEM-1 when in TEM-30
Arg244 is replaced by a Ser residue (220-fold less active, Ki
from 0.04 to 8.8 μM). In terms of binding interaction, the
energetic cost is 3.18 kcal/mol (ΔΔG2), suggesting a critical
interaction with Arg244. On the other hand, varying the
inhibitor structure by masking the carboxylate functionality as
with the keto derivatives 4, the inhibitor loses activity again vs
TEM-1 wild-type (120-fold less active, Ki from 0.04 vs 4.8 μM,
ΔΔG1 2.8 kcal/mol), supporting the hypothesis of an H-bond
between the carboxylate and Arg244. The following double-
mutation steps, when both the enzyme and inhibitor are
“mutated,” conﬁrmed this ﬁnding. The binding energy of the
keto derivative 4 vs TEM-30 with respect to compound 5 vs
TEM-30 did not change (less than 1-fold, Ki 8.8 vs 9.9 μM,
respectively, ΔΔG4 0.07 kcal/mol). Moreover, when 4 was
tested against TEM-30, the aﬃnity with respect to the binding
vs TEM-1 drops by only 2-fold (Ki from 4.8 vs 9.9 μM, ΔΔG3
0.43 kcal/mol). When we calculated the ΔΔΔG for the four
mutation steps, we found that the binding energy contribution
of the carboxylate group vs Arg244 was in perfect agreement
with the presence of an H-bond (Scheme 2b: DPA cycle, ΔΔG1
− ΔΔG4 = 2.73 kcal/mol, ΔΔG2 − ΔΔG3 = 2.75 kcal/mol).
We can certainly aﬃrm that in TEM-1, Arg244 picks up the H-
bond interactions with the carboxylate group of compound 5,
as crystallographically observed in the compound 5−CTX-M-9
complex, where in turn Arg276 is primarily involved in key
interactions with compound 5 as well as several well-ordered
water molecules. Superposition of the CTX-M-9−5 complex
with TEM-1 structure supports and clariﬁes our ﬁnding: TEM-
1 Arg276 corresponds in CTX-M-9 to Asn276; however, TEM-
1 Arg244 is in the proximity of the compound 5 carboxylate
group and can easily pick up H-bond interactions as Arg276
does in CTX-M-9 (Figure 4).
■ DISCUSSION AND CONCLUSION
The identiﬁcation of compound 5 as a novel, non-β-lactam-
based broad-spectrum inhibitor of class A and class C β-
lactamases is a promising result in the bacterial resistance
mediated by BLs.
The purpose of our studies was, beginning with a known,
nonextended spectrum lead, to take advantage of key regions
present along all BL serine-based active site responsible for
binding recognition, e.g., the carboxylate binding domain, in
order to introduce broad-spectrum activity.
Our designed ligand 5, through the introduction of a new
functional group in the starting lead 1, exhibits low nanomolar
aﬃnity vs CTX-M-9, TEM-1, and AmpC BLs. The gain in
aﬃnity vs class A with respect to the starting lead 1 was 1250-
fold vs CTX and vs TEM-1. Comparing compound 5 activity
proﬁle with that of the glycylboronic derivative SMS2, we
found that its potency remains unchanged vs TEM-1 (0.040
and 0.064 μM, respectively) while it is reduced toward AmpC
(0.090 vs 0.001 μM, respectively). Interestingly compound 5
gains aﬃnity toward CTX-M-9 (0.040 vs 0.578 μM).
The results highlight the importance in inhibitor binding
recognition of Arg276 in CTX-M-9 as well as Arg244 in TEM-
1; both residues, which are part of the C3(4′)carboxylate
consensus binding pocket and common to all serine-active BLs,
have been observed to interact with β-lactam substrates in X-ray
complexes with CTX-M-9 and TEM-1. Therefore, our studies
suggested that these residues are hot spots useful for broad-
spectrum BL inhibitor design.
Comparing the CTX-M-9−compound 5 (4LEN) complex
and the glycil boronic derivative SMS2 binding CTX-M-9
(1YM1), we see that the carboxylate lateral chain is oriented as
we predicted in the design, H-bonding to those residues, which
are highly conserved in CTX-M-9 and present in TEM-1, that
were intentionally targeted (Figure 2b, Figure 4).
Scheme 2. Double Perturbation Analysis: (a) Ligands, (b)
Double Perturbation Analysis Cyclea
aThermodynamic cycle to quantify the hydrogen bond energy
between Arg244 and 5. E = wild-type enzyme, E′ = mutant enzyme.
L = wild-type ligand, L′ = “mutant” ligand. ΔΔΔG = (ΔΔG1 −
ΔΔG4) or (ΔΔG2 − ΔΔG3). E = Tem-1, E′ = Tem-30 R244S. L = 5,
L′ = 4. ΔΔΔG1−4 = 2.73 kcal/mol. ΔΔΔG2−3 = 2.75 kcal/mol.
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In addition, the lateral chain of compound 5 interacts with an
opened part of the active site, in a diﬀerent conformation in
chain A with respect to chain B, highlighting a certain mobility
and ﬂexibility in the interactions between ligand and protein. In
both binding sites, several well-ordered water molecules
participate in an extended H-bond network that contribute to
stabilize the complex. In compound 5, the rigidity conferred to
the lateral chain by the double bond probably contributes to
the overall binding energy due to its restricted mobility,
resulting in a tighter binding.
Despite its novelty and broad-spectrum enzymatic activity,
compound 5 resulted in being unstable in microbiology assay
conditions over time (data not shown). These ﬁnding directed
the design and synthesis of more stable analogues of 5 now
under development.
As a ﬁnal comment, structurally guided optimization of novel
extended BL inhibitors active against class A and C has
conﬁrmed binding hot spots that can be targeted to produce
high-aﬃnity inhibitors. These hot spots, i.e., the carboxylate
binding domain, are shared by therapeutically important groups
of BLs, suggesting the hot spots’ potential for broad-spectrum
inhibition of BLs. The nanomolar potency of 5 poses this
compound as an interesting broad-spectrum inhibitor of BLs,
which deserves further investigation.
■ EXPERIMENTAL METHODS
Synthesis. 5-Methylbenzo[b]thiophene and benzo[b]thien-2-yl-
boronic acid were purchased from Lancaster. All reagents were
purchased from Sigma-Aldrich and Fluka and were of reagent grade.
Reaction progress was monitored by TLC on precoated silica gel 60
F254 plates (Merck). Silica gel (60 M; 230−400 mesh, ASTM) was
used for column chromatography. The purity of all synthesized
compounds was determined by elemental analyses, performed on a
PerkinElmer 240C instrument, and all values were within ±0.4% of the
theoretical values (data not shown). Yields refer to puriﬁed products
and were not optimized. All compounds were characterized by 1H
NMR and 13C NMR on AC200 and Bruker MX400 WB instruments
(CIGS, University of Modena e Reggio Emilia). Unless otherwise
stated, spectra were recorded in DMSO-d6 or CDCl3. Chemicals shifts
are reported in ppm from tetramethylsilane as an internal standard.
LC-MSIT analysis was performed through HPLC Agilent 1200 Ion
Trap LC/MS Agilent 6310 device. Source of ionization: Electrospray.
Column: ZORBAX SB-C18 2.1 mm × 30 mm, particles of 3.5 μM.
2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]-
thiophene (2). To 0.30 g (1.68 mmol) of benzo[b]thien-2-ylboronic
acid (1) in dry diethyl ether (40 mL), 2,3-dimethyl-2,3-butanediol
(0.199 g, 1.68 mmol), and a catalytic amount of triﬂuoroacetic acid
was added. The mixture was stirred under nitrogen for 15 min. The
solvent was removed under vacuum and crude residue extracted with
n-pentane, producing 2. Yield: 0.381 g, 87%. 1H NMR (DMSO): δ
1.31 (s, 12H), 7.42 (m, 2H), 7.91 (s, 1H), 7.95 (m, 1H), 8.02 (m,
1H). Anal. (C14H17BO2S) C, H, N.
2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]-
thiophene-3-carbaldehyde (3). Tin chloride (575 μL, 4.9 mmol)
was added dropwise to a stirred solution of 2 (0.425 g, 1.63 mmol) in
dry dichloromethane (6 mL) at −20 °C under nitrogen.
Dichloromethyl methyl ether (177 μL, 1.96 mmol) was added
dropwise and the mixture allowed to warm to 0 °C. After the mixture
had been stirred for 7 h, it was poured into diluted hydrochloric acid
and extracted with dichloromethane CH2Cl2. The extracts were
washed with sodium chloride solution, dried with sodium sulfate, and
evaporated. The residue was crystallized with dichloromethane/n-
hexane, producing 3. Yield: 0.415 g, 75%. 1H NMR (CDCl3): δ 1.41
(s, 12H), 7.50 (m, 2H), 7.90 (m, 1H), 8.85 (m, 1H), 10.69 (s, 1H).
Anal. (C15H17BO3S) C, H, N.
4-[2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzo-
[b]thiophen-3-yl]-but-3-en-one (4). A mixture of 3 (0.1 g, 0.347
mmol) and 1-(triphenylphosphoranylidene)-2-propanone (0.11 g,
0.348 mmol) in dry dichloromethane (1.5 mL) was stirred at room
temperature under nitrogen for 24 h. The solvent was removed under
vacuum, and the crude residue was extracted several times with diethyl
ether to remove triphenylphosphine oxide. The organic phase was
Figure 4. Interpreting DPA results. Compound 5 (carbon atoms in green) in binary complex with CTX-M-9 (carbon atoms in gray) is superimposed
TEM-1 (carbon atoms in orange). Key residue Arg276, which in CTM-M-9 interacts with compound 5 carboxylate group, is replaced by Asn276 in
TEM-1. However, in TEM-1, as suggested from DPA, key interaction could be picked up from Arg244, oriented at H-bond distance from compound
5. Picture was prepared using CCP4mg.53
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dried on magnesium sulfate and the solvent removed under vacuum,
producing 4 as a white crystalline solid. Yield: 0.055 g, 48%.
3-[2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzo-
[b]thiophen-3-yl]-acrylic Acid (5). A mixture of 3 (0.30 g, 1.04
mmol) and tert-butoxycarbonylmethylene-triphenylphosphorane
(0.391 g, 1.04 mmol) in dry dichloromethane (4 mL) was stirred at
room temperature under nitrogen for 24 h. The solvent was removed
under vacuum, and the crude residue was extracted several times with
diethyl ether to remove triphenylphosphine oxide. After solvent
removal, the crude extract was treated with dichloromethane/
triﬂuoroacetic acid 50% and stirred at room temperature for 2 h.
The solvent was removed under vacuum and residue washed with
diethyl ether, producing 5 as a white crystalline solid. Yield: 0.120 g,
35%. 1H NMR (DMSO): δ 1.34 (s, 12H), 6.59 (d, 1H), 7.52 (m, 2H),
8.07 (dd, 1H), 8.18 (dd, 1H), 8.25 (d, 1H), 12.41 (b all., 1H). Anal.
(C17H19BO4S) C, H, N.
Inhibition Assays. Versus AmpC. Boronic acids were dissolved in
DMSO stock solutions at 50 mM; more dilute stocks were
subsequently prepared as necessary by dissolving them in 50 mM
phosphate buﬀer at pH 7. Compounds isolated as pinacol-protected
boronic acid were tested without further ester cleavage reaction;
compounds were hydrolyzed to the free acid form by dissolving them
in 50 mM phosphate buﬀer at pH 7.4.18,41 AmpC from E. coli was
expressed and puriﬁed to homogeneity as described.36 Kinetic
measurements were performed using nitroceﬁn as a substrate in 50
mM Tris buﬀer, pH 7.0, and monitored in an HP8453 UV−vis
spectrophotometer. The Km of nitroceﬁn for AmpC in this buﬀer was
127 μM. The concentration of AmpC was determined spectrophoto-
metrically in concentrated stock solutions made from lyophilized
powder and subsequently diluted; this enzyme had been previously
expressed and puriﬁed as described.23 The concentration of enzyme
was 1.75 nM. Inhibition Ki values were obtained from IC50 plots
assuming competitive inhibition, an assumption consistent with both
previous inhibition patterns in this series and with experiments
investigating the eﬀect of increasing substrate concentrations (not
shown).42
Versus CTX. Boronic acids were dissolved in DMSO stock solutions
at 50 mM; more dilute stocks were subsequently prepared as necessary
by dissolving them in 50 mM phosphate buﬀer at pH 7. CTX-M-9 was
produced from a modiﬁed pET-9a plasmid in E. coli BL21 (DE3). The
protein was puriﬁed by ion exchange and gel ﬁltration, as previously
described.43 Enzymes were diluted from stock solutions to a ﬁnal
concentration of 1.5 nM. The enzyme assay was carried out in 50 mM
potassium phosphate (pH 7.0) at room temperature and monitored in
an HP8453 UV−vis spectrophotometer. The reaction was monitored
at 340 nm using 6-β-furylacryloylamido-penicillanic acid (100 μM,
FAP, Calbiochem) as substrate (the Km values for CTX-M-9 and
CTX-M-16 were 17 and 6.5 μM, respectively). The progress curves
were measured at least three times for each substrate.25 Ki values were
obtained by comparing the progress curves in the presence and
absence of the inhibitor using the method described by Waley.44
Versus TEM-1. Boronic acids were dissolved in DMSO stock
solutions at 50 mM; more dilute stocks were subsequently prepared as
necessary by dissolving them in 50 mM phosphate buﬀer at pH 7.
TEM-1 enzyme was expressed and puriﬁed as described.45 TEM-1
enzyme assays used 100 mM 6-β-furylacryloylamido-penicillanic acid
(FAP, Calbiochem) as a substrate, monitoring absorbance changes at
340 nm on an HP8453 spectrophotometer. Reactions were initiated
with addition of 0.3 nM enzyme, using the same buﬀer as in the AmpC
assays. The Ki values for compounds were obtained by the comparison
of the progress curves in the presence and absence of the inhibitor.
This method correlates well with full Ki analysis through coupled
substrate and inhibitor concentration variation.42 TEM-30 used for
double perturbation thermodynamic cycle was prepared as reported.46
Crystallization. Cocrystals of CTX-M-9 enzyme in complex with 5
were grown by vapor diﬀusion in hanging drops equilibrated over a
well solution of 1.6 M potassium phosphate buﬀer (pH 8.8) using
micro seeding techniques and microcrystals of CTX-M-9 previously
grown under the same conditions. To a solution of 15 mg/mL protein
in 5 mM Tris (pH 7.0) and 30 mM NaCl was added an equal volume
of 1 mM inhibitor in a solution of 5% DMSO, 1.25 M potassium
phosphate (pH 8.8). Crystals appeared in 8−24 h after equilibration at
20 °C. Before data collection, crystals were immersed in a cryo-
protectant solution of 30% sucrose, 1.8 M potassium phosphate (pH
8.8) for approximately 30 s and then were ﬂash frozen in liquid
nitrogen.25
Data Collection and Structure Determination. Data were
measured at 100 K using an ADSC−CCD detector on Beamline 8.3.1
of the Advanced Light Source at Lawrence Berkley National
Laboratory. Reﬂections were indexed, integrated, and scaled using
the HKL software package.47 The space group was P21, with two
molecules in the asymmetric unit. Phases were calculated by molecular
replacement with the program EPMR22 using the apoenzyme
structure of CTX-M-9, with the water molecules and ions removed
(Table 3).30 The complex structures of CTX-M-9 with compound 5 at
1.50 Å resolution were reﬁned using the maximum likelihood method
in CNS, including simulated annealing with an initial temperature of
2000 K, positional minimization, and individual B-factor reﬁnement,
with a bulk solvent correction.48 σA-weighted electron density maps
were calculated using CNS and used in the steps of manual model
rebuilding with the program Coot.49 The ﬁnal cycle of reﬁnement was
performed using the software Refmac from the CCP4 suite.50,51 Cross-
validation was employed throughout, and 5% of the data were used for
the Rfree calculation. The stereochemical quality of the models was
monitored periodically with the program Procheck.52,53
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